The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.60
Ask: 13.90
Change: 0.15 (1.10%)
Spread: 0.30 (2.206%)
Open: 13.60
High: 13.75
Low: 13.75
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: CentralNic and Pebble tip 2021 earnings rise

Mon, 17th Jan 2022 17:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

CentralNic Group PLC - London-based domain name registry and registrar services firm - Says organic growth "accelerated" in fourth quarter, which CentralNic attributes to "significant investment programme". For 2021, organic growth was 37%. Expects annual revenue of USD450 million and adjusted earnings before interest, tax, depreciation and amortisation of around USD45 million. This would be ahead of revenue consensus of USD383 million and adjusted Ebitda consensus of USD42.9 million. Would represent 70% revenue growth and 47% climb in adjusted Ebitda from 2020.

----------

Pebble Group PLC - Manchester-based technology and services for promotional products industry - Says revenue for 2021 to be around GBP115 million, up from GBP82.4 million in 2020 and beating 2019's GBP107.2 million, which was before onset of pandemic. It expects an adjusted Ebitda of GBP15 million, up from GBP9.8 million in 2020 but down a touch from GBP15.2 million in 2019.

----------

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Licenses RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. "Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage," company says. "The candidate, which will be developed by Poolbeg as POLB 002, was developed at the University of Warwick and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock."

----------

Midatech Pharma PLC - Cardiff-based drug delivery technology company - Extends research and development pact with Janssen Pharmaceutical NV, owned by Johnson & Johnson. "Under the extended collaboration the company will focus on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the company's Q-Sphera technology," Midatech says.

----------

Helium One Global Ltd - London-based exploration & development company - Says remote sensing work at Rukwa, Eyasi and Balangida project areas finds "additional helium anomalies". "Evidence of a robust helium anomaly across the Tai structure where drilling last year encountered numerous helium shows," company says. "Multiple surface anomalies identified within all three basins that require follow up geophysical investigation."

----------

Future Metals NL - Australia-focused platinum group metals explorer - Reports "further high-grade PGM assay results" at Panton project in Australia. "Metallurgical flotation test work is underway on both high-grade and low-grade representative composite samples," Future Metals says. Notes results pending for further 52 drill holes.

----------

88 Energy Ltd - Alaska-focused oil exploration and appraisal company - Says permit to drill Merlin-2 in final stages of review by Bureau of Land Management in Alaska. Affirms project timeline. Company explains: "Permitting and planning for the Merlin-2 well is now largely complete, with the well on track to spud in February 2022. The Merlin-2 permit to drill is in the final stages of review by the BLM and is on schedule to be issued ahead of rig mobilisation."

----------

Ncondezi Energy Ltd - coal-fired power project in Mozambique - Updates on power project in Tete, Mozambique. Says awaiting further clarity on China's position on financing coal projects. Adds China Machinery Engineering Corp "remains committed" to project. Ncondezi is funded to end of first half of 2022, company adds.

----------

Drumz PLC - London-based investment company - Says 25% owned investee Acuity Risk Management Ltd wins several new customers for Stream risk management product. Says major broadcaster with "global reach" adopts Stream, ass does a "multinational German industrial control and automation company".

----------

H&T Group PLC - Surrey, England-based pawnbroker - Expects pretax profit for 2021 to be within range of current market expectations, which stand between GBP9.0 million and GBP10.1 million. "Demand for pledge lending has now fully recovered to pre-pandemic levels, with positive momentum across the customer spectrum and in all geographies. The months of November and December saw particularly strong borrowing demand, with lending volumes in December ahead of expectations and at record levels. Loan-to-value ratios have been maintained. Redemption rates remain stable and above historic norms," H&T says. "Retail sales have continued to remain robust, with consistently strong demand for high quality pre-owned watches and jewellery both online and in H&T's store network."

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more
17 Oct 2023 10:49

Poolbeg Pharma shares up on metabolic drug collaboration agreement

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.